178 related articles for article (PubMed ID: 21639139)
1. Cell-specific targeting by heterobivalent ligands.
Josan JS; Handl HL; Sankaranarayanan R; Xu L; Lynch RM; Vagner J; Mash EA; Hruby VJ; Gillies RJ
Bioconjug Chem; 2011 Jul; 22(7):1270-8. PubMed ID: 21639139
[TBL] [Abstract][Full Text] [Related]
2. Enhanced targeting with heterobivalent ligands.
Xu L; Vagner J; Josan J; Lynch RM; Morse DL; Baggett B; Han H; Mash EA; Hruby VJ; Gillies RJ
Mol Cancer Ther; 2009 Aug; 8(8):2356-65. PubMed ID: 19671749
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.
Alleti R; Vagner J; Dehigaspitiya DC; Moberg VE; Elshan NG; Tafreshi NK; Brabez N; Weber CS; Lynch RM; Hruby VJ; Gillies RJ; Morse DL; Mash EA
Bioorg Med Chem; 2013 Sep; 21(17):5029-38. PubMed ID: 23890524
[TBL] [Abstract][Full Text] [Related]
4. Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors.
Josan JS; Vagner J; Handl HL; Sankaranarayanan R; Gillies RJ; Hruby VJ
Int J Pept Res Ther; 2008 Dec; 14(4):293-300. PubMed ID: 19714261
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor.
Fernandes SM; Lee YS; Gillies RJ; Hruby VJ
Bioorg Med Chem; 2014 Nov; 22(22):6360-5. PubMed ID: 25438759
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).
Handl HL; Sankaranarayanan R; Josan JS; Vagner J; Mash EA; Gillies RJ; Hruby VJ
Bioconjug Chem; 2007; 18(4):1101-9. PubMed ID: 17591746
[TBL] [Abstract][Full Text] [Related]
7. Heterobivalent ligands target cell-surface receptor combinations in vivo.
Xu L; Josan JS; Vagner J; Caplan MR; Hruby VJ; Mash EA; Lynch RM; Morse DL; Gillies RJ
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21295-300. PubMed ID: 23236171
[TBL] [Abstract][Full Text] [Related]
8. Optimization of time-resolved fluorescence assay for detection of europium-tetraazacyclododecyltetraacetic acid-labeled ligand-receptor interactions.
De Silva CR; Vagner J; Lynch R; Gillies RJ; Hruby VJ
Anal Biochem; 2010 Mar; 398(1):15-23. PubMed ID: 19852924
[TBL] [Abstract][Full Text] [Related]
9. Rigid linkers for bioactive peptides.
Vagner J; Handl HL; Monguchi Y; Jana U; Begay LJ; Mash EA; Hruby VJ; Gillies RJ
Bioconjug Chem; 2006; 17(6):1545-50. PubMed ID: 17105235
[TBL] [Abstract][Full Text] [Related]
10. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
11. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M; Liu G; Pinon DI; Miller LJ
Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
13. A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH
Lensing CJ; Adank DN; Wilber SL; Freeman KT; Schnell SM; Speth RC; Zarth AT; Haskell-Luevano C
ACS Chem Neurosci; 2017 Jun; 8(6):1262-1278. PubMed ID: 28128928
[TBL] [Abstract][Full Text] [Related]
14. Homogeneous fluorescence anisotropy-based assay for characterization of ligand binding dynamics to GPCRs in budded baculoviruses: the case of Cy3B-NDP-α-MSH binding to MC4 receptors.
Veiksina S; Kopanchuk S; Mazina O; Link R; Lille A; Rinken A
Methods Mol Biol; 2015; 1272():37-50. PubMed ID: 25563175
[TBL] [Abstract][Full Text] [Related]
15. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat.
Adan RA; Szklarczyk AW; Oosterom J; Brakkee JH; Nijenhuis WA; Schaaper WM; Meloen RH; Gispen WH
Eur J Pharmacol; 1999 Aug; 378(3):249-58. PubMed ID: 10493100
[TBL] [Abstract][Full Text] [Related]
16. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors.
Haskell-Luevano C; Holder JR; Monck EK; Bauzo RM
J Med Chem; 2001 Jun; 44(13):2247-52. PubMed ID: 11405661
[TBL] [Abstract][Full Text] [Related]
17. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and in vitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC
Lindner S; Fiedler L; Wängler B; Bartenstein P; Schirrmacher R; Wängler C
Eur J Med Chem; 2018 Jul; 155():84-95. PubMed ID: 29864700
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.
Xiang Z; Proneth B; Dirain ML; Litherland SA; Haskell-Luevano C
Biochemistry; 2010 Jun; 49(22):4583-600. PubMed ID: 20462274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
